News

US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Kalkine Media2h
FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista
KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
BioPharma Dive3h
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Fierce Pharma5h
KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
pharmaphorum7h
KalVista bags FDA approval for delayed oral HAE drug
KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...
FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
Managed Healthcare Executive39m
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
Ekterly comes in the form of a 300 mg tablet. The recommended dosage is 600 mg split into two doses taken at the earliest sign of an attack, according to the prescribing information. Additional ...
BioSpace6h
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals' Ekterly (sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 ...
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...